Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 11/2019

01-11-2019 | osteosarcoma | Original Article

CDC20 and its downstream genes: potential prognosis factors of osteosarcoma

Authors: Man-si Wu, Qing-yu Ma, Dong-dong Liu, Xiao-juan Li, Li-juan Deng, Nan Li, Jingnan Shen, Zhiqiang Zhao, Jia-xu Chen

Published in: International Journal of Clinical Oncology | Issue 11/2019

Login to get access

Abstract

Background

We investigated the microarray data GSE42352 to identify genes that can be used as prognosis factors in osteosarcoma.

Methods

Gene Ontology (GO) biological process analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of Cytoscape ClueGo were used in verifying the function of different genes. Realtime-PCR were used to confirm the microarray results. 83 patient samples were collected and underwent Kaplan–Meier survival analysis and multivariate analysis to predict the prospect of genes using as prognosis factors.

Results

After analyzing the microarray data GSE42352, mitosis metaphase to anaphase-related genes CDC20, securin, cyclin A2 and cyclin B2 were found to be overexpressed in osteosarcoma cell lines. Kaplan–Meier survival analysis showed that overexpression of these genes can predict poor prognosis outcomes in osteosarcoma patients. Furthermore, any combination of the four genes seems to be more effective in predicting osteosarcoma outcomes than any of these genes alone.

Conclusions

CDC20 and its downstream substracts securin, cyclin A2 and cyclin B2 are good factors that can predict prognosis outcomes in osteosarcoma. Any two combination of these four genes are more effective to be used as osteosarcoma prognosis factors.
Appendix
Available only for authorised users
Literature
1.
Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ(R)) (2002) Health Professional Version, in PDQ Cancer Information Summaries. Bethesda (MD).
2.
Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115(7):1531–1543CrossRef
3.
Isakoff MS et al (2015) Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol 33(27):3029–3035CrossRef
4.
Kuijjer ML et al (2013) IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 13:245CrossRef
5.
McLean JR et al (2011) State of the APC/C: organization, function, and structure. Crit Rev Biochem Mol Biol 46(2):118–136CrossRef
6.
Stemmann O et al (2001) Dual inhibition of sister chromatid separation at metaphase. Cell 107(6):715–726CrossRef
7.
Bharadwaj R, Yu H (2004) The spindle checkpoint, aneuploidy, and cancer. Oncogene 23(11):2016–2027CrossRef
8.
Zur A, Brandeis M (2001) Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis. EMBO J 20(4):792–801CrossRef
9.
Shirayama M et al (1999) APC(Cdc20) promotes exit from mitosis by destroying the anaphase inhibitor Pds1 and cyclin Clb5. Nature 402(6758):203–207CrossRef
10.
Geley S et al (2001) Anaphase-promoting complex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J Cell Biol 153(1):137–148CrossRef
11.
Nasmyth K (2002) Segregating sister genomes: the molecular biology of chromosome separation. Science 297(5581):559–565CrossRef
12.
Nam HJ, van Deursen JM (2014) Cyclin B2 and p53 control proper timing of centrosome separation. Nat Cell Biol 16(6):538–549CrossRef
13.
Shannon P et al (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–2504CrossRef
14.
Pakos EE et al (2009) Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer 45(13):2367–2375CrossRef
15.
Collins M et al (2013) Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol 31(18):2303–2312CrossRef
16.
Gorlick R et al (1999) Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17(9):2781–2788CrossRef
17.
Onda M et al (1996) ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77(1):71–78CrossRef
18.
Kilpatrick SE et al (2001) Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 14(12):1277–1283CrossRef
19.
Feugeas O et al (1996) Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14(2):467–472CrossRef
20.
Heinsohn S et al (2007) Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. Int J Oncol 30(5):1205–1214PubMed
21.
Goto A et al (1998) Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. Jpn J Cancer Res 89(5):539–547CrossRef
22.
Serra M et al (2006) May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol 29(6):1459–1468PubMed
23.
Shang G, Ma X, Lv G (2018) Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells. Cell Cycle 17(1):43–52CrossRef
24.
Gao Y et al (2018) Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells. Oncol Rep 40(2):841–848PubMed
25.
Hu K et al (2014) Targeting the anaphase-promoting complex/cyclosome (APC/C)- bromodomain containing 7 (BRD7) pathway for human osteosarcoma. Oncotarget 5(10):3088–3100CrossRef
26.
Yu H (2007) Cdc20: a WD40 activator for a cell cycle degradation machine. Mol Cell 27(1):3–16CrossRef
27.
Ouellet V et al (2006) Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119(3):599–607CrossRef
28.
Penas C, Ramachandran V, Ayad NG (2011) The APC/C ubiquitin ligase: from cell biology to tumorigenesis. Front Oncol 1:60PubMed
29.
Karra H et al (2014) Cdc20 and securin overexpression predict short-term breast cancer survival. Br J Cancer 110(12):2905–2913CrossRef
30.
Shekhar R et al (2019) The microRNAs miR-449a and miR-424 suppress osteosarcoma by targeting cyclin A2 expression. J Biol Chem 294(12):4381–4400CrossRef
31.
Tschop K, Engeland K (2007) Cell cycle-dependent transcription of cyclin B2 is influenced by DNA methylation but is independent of methylation in the CDE and CHR elements. FEBS J 274(20):5235–5249CrossRef
32.
Navid F et al (2017) A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. Int J Cancer 141(7):1469–1477CrossRef
33.
Deng Z et al (2016) Histone deacetylase inhibitor trichostatin a promotes the apoptosis of osteosarcoma cells through p53 signaling pathway activation. Int J Biol Sci 12(11):1298–1308CrossRef
34.
Shor AC et al (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67(6):2800–2808CrossRef
35.
Gobin B et al (2014) Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models. PLoS One 9(3):e90795CrossRef
Metadata
Title
CDC20 and its downstream genes: potential prognosis factors of osteosarcoma
Authors
Man-si Wu
Qing-yu Ma
Dong-dong Liu
Xiao-juan Li
Li-juan Deng
Nan Li
Jingnan Shen
Zhiqiang Zhao
Jia-xu Chen
Publication date
01-11-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 11/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01500-3

Other articles of this Issue 11/2019

International Journal of Clinical Oncology 11/2019 Go to the issue

Original Article

The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas

Original Article

Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

Original Article

Efficacy of daikenchuto, a traditional Japanese Kampo medicine, for postoperative intestinal dysfunction in patients with gastrointestinal cancers: meta-analysis

Original Article

Forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) overexpression is associated with poor prognosis in patients with cervical cancer

Original Article

Clinical results of carbon-ion radiotherapy with separation surgery for primary spine/paraspinal sarcomas

Original Article

Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits